http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2351456-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_648d978baf1c77bbb31249486dfb60d0 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6837 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12 |
| filingDate | 2009-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2011-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bfdb4a62c9049232ee3bd80bdeee513d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_88ed3f84fe95c641ece246f444fafcb4 |
| publicationDate | 2011-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2351456-B1 |
| titleOfInvention | IN VITRO METHOD FOR THE FORECAST OR PREDICTION OF THE RESPONSE BY PATIENTS WITH REUMATOID ARTHRITIS TO THE TREATMENT WITH AGENTS RECOGNIZING THE CD20 MEMBRANE RECEIVER OF THE LYMPHOCYTES B |
| abstract | In vitro method for the prognosis or prediction of the response by patients with rheumatoid arthritis to treatment with agents that recognize the CD20 membrane receptor of B lymphocytes. The method of the invention comprises the determination in a blood sample of said patients. and by quantifying the level of transcriptional expression (mRNA), before starting treatment, of at least one of the genes selected from the group: ARG1, CPD, TRAF1, C1QA, LRRN3, HLA-DQA1, NLK, TLR4, LOC89944, TOM1L1, BACH, NCALD, EIF2C2, NFIC, PCDHB7, FLJ32770, ARID3A, C14ORF9, CSNK1E, BCAS1, TEAD2, C6orf145 and SNTA1; and the comparison of said level of expression with respect to the expression values previously obtained from patients who proved to be responders to the treatment or not responders to it. |
| priorityDate | 2009-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 194.